Compare BNR & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNR | SLP |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Medical Specialities | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.2M | 293.5M |
| IPO Year | 2019 | 1996 |
| Metric | BNR | SLP |
|---|---|---|
| Price | $28.78 | $12.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 11.9K | ★ 386.9K |
| Earning Date | 01-01-0001 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $59,577,000.00 |
| Revenue This Year | $136.32 | $2.64 |
| Revenue Next Year | N/A | $6.01 |
| P/E Ratio | ★ N/A | $406.33 |
| Revenue Growth | N/A | ★ 10.52 |
| 52 Week Low | $2.18 | $11.76 |
| 52 Week High | $41.72 | $36.43 |
| Indicator | BNR | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 20.95 |
| Support Level | $28.28 | $11.76 |
| Resistance Level | $34.26 | $14.78 |
| Average True Range (ATR) | 2.86 | 0.89 |
| MACD | -1.00 | -0.34 |
| Stochastic Oscillator | 13.37 | 8.09 |
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.